9:22 AM
Leo Group India
| ||
| ||
| Teva shares jump on positive Copaxone patent ruling IBNLive.com By Steven Scheer JERUSALEM (Reuters) - Teva Pharmaceutical Industries rose more than 11 percent on Sunday after a U.S. court upheld Tevas patents for ... See all stories on this topic » | ||
| Shengtai Pharmaceutical, Inc. Special Committee Selects Financial ... Business Review India (press release) WEIFANG, Shandong, China, June 23, 2012 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the ... See all stories on this topic » | ||
| Pharma cos stay mum as govt seeks details of overcharging Hindustan Times Even after four months of receiving overcharging notices from the department of pharmaceuticals (DoP), not even one of the 500-odd pharma companies have ... See all stories on this topic » | ||
| OPINION: Pharmaceutical reps overtime ruling protects FLSA ... Business Insurance The U.S. Supreme Court prevented a potential flood of litigation with last week's ruling in a case involving eligibility for overtime pay. As we report on page 3, ... See all stories on this topic » | ||
| Teva Jumps Most Since 2000 on Copaxone Ruling in US Businessweek Teva Pharmaceutical Industries Ltd. (TEVA) jumped the most in more than 12 years after a U.S. federal district judge ruling may block generic versions of its ... See all stories on this topic » | ||
| Leader upgrades Teva Globes Leader Capital Markets today raised its recommendation for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) to "Buy" from "Outperform", with a ... See all stories on this topic » | ||
| Teva soars on Copaxone patents victory Globes Shares in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) are up 7.95% at NIS 157.50 on the Tel Aviv Stock Exchange, following a victory by ... See all stories on this topic » | ||
| You Can't Have Free Trade and Price Controls: Pharmaceutical ... Forbes This is a nice example of the fact that in economics there are no such things as solutions. There are only possible trade offs. In this case the trade off is between ... See all stories on this topic » | ||
| Teva's problems are delayed, not solved Globes 24 June 12 18:38, Gali Weinreb. The legal decision does not solve any of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA; TASE: TEVA) strategic problems. See all stories on this topic » |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment